Home Physical Sciences Crystal structure of 1-(5-bromo-2-(4-methoxyphenyl)-1H-indol-7-yl)ethanone oxime, C17H15BrN2O2
Article Open Access

Crystal structure of 1-(5-bromo-2-(4-methoxyphenyl)-1H-indol-7-yl)ethanone oxime, C17H15BrN2O2

  • Malose J. Mphahlele EMAIL logo
Published/Copyright: July 17, 2018

Abstract

C17H15BrN2O2, monoclinic, P21/c, a = 14.4197(9) Å, b = 7.5423(5) Å, c = 14.9602(9) Å, β = 114.665(2)°, V = 1478.59(16) Å3, Z = 4, Rgt(F) = 0.0196, wRref(F2) = 0.0526, T = 173(2) K.

CCDC no.: 1822505

The crystal structure is shown in the figure. Tables 1 and 2 contain details on crystal structure and measurement conditions and a list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal:Colourless prism
Size:0.53 × 0.23 × 0.20 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:2.79 mm−1
Diffractometer, scan mode:Bruker D8 Venture, ω (0.3°)
θmax, completeness:28.0°, >99%
N(hkl)measured, N(hkl)unique, Rint:63347, 3547, 0.026
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 3375
N(param)refined:201
Programs:Bruker [1], WinGX [2], SHELX [3]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
Br10.63095(2)0.33782(2)0.04747(2)0.02122(5)
O10.43536(7)0.67988(15)0.41273(7)0.0259(2)
H10.4539020.7181490.4703520.039*
O21.03667(7)0.39664(15)0.92571(7)0.0244(2)
N10.71264(8)0.46782(14)0.46882(7)0.0157(2)
H1A0.6767860.5104020.4992610.019*
N20.52037(8)0.61063(16)0.40112(8)0.0199(2)
C10.65295(10)0.38653(17)0.17989(9)0.0168(2)
C20.57369(9)0.46502(16)0.19660(9)0.0163(2)
H20.5118980.4955490.1423150.02*
C30.58440(9)0.49900(16)0.29225(9)0.0146(2)
C40.67880(9)0.45241(16)0.36876(9)0.0149(2)
C50.75886(9)0.37437(16)0.35071(9)0.0160(2)
C60.74481(10)0.33807(16)0.25409(10)0.0172(2)
H60.7965110.2823460.2403570.021*
C70.84197(10)0.34631(16)0.44407(9)0.0176(2)
H70.906230.2956470.455370.021*
C80.81195(9)0.40599(17)0.51449(9)0.0164(2)
C90.86974(9)0.41048(16)0.62170(9)0.0161(2)
C100.97385(9)0.44912(18)0.66198(9)0.0187(2)
H101.0057610.4763870.6194790.022*
C111.03174(9)0.44848(18)0.76307(9)0.0191(2)
H111.1023780.4765240.7893420.023*
C120.98582(10)0.40667(17)0.82537(9)0.0182(2)
C130.88175(10)0.3686(2)0.78648(10)0.0236(3)
H130.8502070.340540.8291910.028*
C140.82429(10)0.37175(19)0.68566(10)0.0216(3)
H140.7532340.3472940.6597160.026*
C151.13840(10)0.4667(2)0.96883(10)0.0248(3)
H15A1.1821270.3975770.9462950.037*
H15B1.1651160.4596581.0406540.037*
H15C1.1374660.5907640.9489860.037*
C160.49967(9)0.57594(16)0.31074(9)0.0155(2)
C170.39748(10)0.6101(2)0.22759(10)0.0247(3)
H17Aa0.3991860.573550.1654250.037*
H17Ba0.3450060.5421130.2381820.037*
H17Ca0.3815540.7368080.2248920.037*
H17Da0.3513110.661430.2535740.037*
H17Ea0.4054920.6928680.1808170.037*
H17Fa0.3689430.4981730.1941070.037*
  1. aOccupancy: 0.5.

Source of material

A stirred mixture of 1-[5-bromo-2-(4-methoxyphenyl)-1H-indol-7-yl]ethanone (0.30 g, 0.87 mmol), hydroxylamine hydrochloride (0.09 g, 1.31 mmol) and pyridine (0.10 g, 1.31 mmol) in ethanol (20 mL) was heated at 80° C for 5 h. The mixture was cooled to room temperature and quenched with an ice-cold water. The product was extracted into chloroform and the combined organic phases were washed with water and dried over anhydrous MgSO4. The salt was filtered off and the solvent was evaporated under reduced pressure. The residue recrystallized from ethanol to the title compound as a white solid (0.25 g, 80%), m.p. 202–204° C; IR: νmax (ATR) 521, 585, 612, 653, 671, 755, 796, 826, 984, 1017, 1172, 1185, 1246, 1323, 1372, 1439, 1460, 1497, 3372, 3518 cm−1; 1H-NMR (DMSO-d6) 2.30 (3H, s, CH3), 3.80 (3H, s, OCH3), 6.80 (1H, s, 3-H), 7.04 (2H, d, J = 8.7 Hz, 3′,5′-H), 7.42 (1H, d, J = 1.2 Hz, 6-H), 7.70 (3H, m, 4-H and 2′,6′-H), 10.84 (1H, s, NH), 11.57 (1H, s, OH); 13C-NMR (DMSO-d6) 11.3, 55.7, 98.0, 112.3, 115.0, 121.4, 122.9, 123.4, 124.2, 126.9, 131.6, 132.2, 139.4, 154.2, 159.8; m/z 359 (100, M + H); HRMS (ES): found 359.0293. C17H16N2O279Br+ requires 359.0395.

Experimental details

Data reduction was carried out using SAINT+ and SADABS [1]. The crystal structure was solved by Direct Methods using SHELXTL. Hydrogen atoms were positioned geometrically and allowed to ride on their respective parent atoms. Hydrogen atoms involved in hydrogen bonding were refined freely [2], [3], [4]. Diagrams and publication material were generated using SHELXTL and PLATON [4].

Comment

The indole nucleus is an important scaffold in numerous natural and synthetic alkaloids and indole have a wide range of application in medicine and materials [5]. Oximes represent important building blocks in the synthesis of amides via the Beckmann rearrangement. The oximes derived from the 1-(2,5-diaryl-1H-indol-7-yl)ethanones, for example, were previously found to undergo trifluoroacetic acid-mediated Beckmann rearrangement to afford the N-(2,5-diaryl-1H-indol-7-yl)-acetamides [6]. The O-mesyl or tosyl-oximes derived from indole derivatives, on the other hand, have been found to react with liquid ammonia at low temperature to afford diaziridines [7]. Recourse to the literature revealed that a bromine atom on the fused benzo ring of an indole framework imparts significant antitumour activity in both the synthetic [8] and the naturally occurring indole derivatives [9]. This knowledge encouraged us to incorporate an acetamide group on 2-aryl-7-acetyl-5-bromoindoles via initial oximation and subsequent Beckmann rearrangement. During this transformation, we were able to obtain crystals of the title compound.

The title crystal structure shows intermolecular {N(1)—H(1)⋯N(2)} and intermolecular {O(2)—H(2)⋯O(1)} hydrogen bonding with no π-stacking of the indole. There is co-planarity between the aromatic rings of the indole. The oxime group is also co-planar with the indole with torsion angle C(4)—C(3)—C(16)—N(2) value of 5°. The hydroxyl group is trans to the indole framework to avoid steric interaction. The methyl group of the 4-methoxy of the molecule, on the other hand, is rotated towards the C11 with the C(15)—O(1) bond length of 1.44 Å, which is typical for a methoxy group attached to an aromatic ring. The geometry of the oxime moiety reveal that the C3 atom is significantly asymmetrically positioned off the six membered ring.

Acknowledgements

The author is grateful to the University of South Africa and the National Research Foundation for financial assistance. Special thanks to Marole M. Maluleka for technical assistance. Prof. A. Lemmerer of the University of the Witwatersrand is acknowledged for X-ray data acquisition using a diffractometer acquired through the NRF National Equipment Programme (UID: 78572).

References

Bruker. SAINT+, version 6.02 (Includes XPREP and SADABS). Bruker AXS Inc., Madison, WI, USA (2004).Search in Google Scholar

Farrugia, L. J.: WinGX suite for small-molecule single-crystal crystallography. J. Appl. Crystallogr. 3 (2012) 837–838.10.1107/S0021889899006020Search in Google Scholar

Sheldrick, G. M.: A short history of SHELX. Acta Crystallogr. A64 (2008) 112–122.10.1107/S0108767307043930Search in Google Scholar

Spek, A. L.: Structure validation in chemical crystallography. Acta Crystallogr. D65 (2009) 148–155.10.1107/S090744490804362XSearch in Google Scholar

Sharma, V.; Kumar, P.; Pathak, D.: Biological importance of the indole nucleus in recent years: a comprehensive review. J. Heterocycl. Chem. 47 (2010) 491–502.10.1002/jhet.349Search in Google Scholar

Mphahlele, M. J.; Mmonwa, M. M.; Choong, Y. S.: Synthesis and evaluation of N-(3-trifluoroacetyl-indol-7-yl) acetamides for potential in vitro antiplasmodial properties. Molecules 22 (2017) 1099–1115.10.3390/molecules22071099Search in Google Scholar

Protasova, I.; Bular, B.; Jung, N.; Bräse, S.: Synthesis of diaziridines and diazirines via resin-bound sulfonyl oximes. Org. Lett. 19 (2017) 34–37.10.1021/acs.orglett.6b03252Search in Google Scholar

Cooper, L. C.; Chicchi, G. G.; Dinnell, K.; Elliott, J. M.; Hollingworth, G. J.; Kurtz, M. M.; Locker, K. L.; Morrison, D.; Shaw, D. E.; Tsao, K.-L.; Watt, A. P.; Williams, A. R.; Swain, C. J.: 2-Aryl indole NK1 receptor antagonists: optimisation of indole substitution. Bioorg. Med. Chem. Lett. 11 (2001) 1233–1236.10.1016/S0960-894X(01)00182-2Search in Google Scholar

Sisa, M.; Pla, D.; Altuna, M.; Francesch, A.; Cuevas, C.; Albericio, F.; Alvarez, M.: Total synthesis and antiproliferative activity screening of (+-)-aplicyanins A, B and E and related analogues. J. Med. Chem. 52 (2009) 6217–6223.10.1021/jm900544zSearch in Google Scholar PubMed

Received: 2018-04-11
Accepted: 2018-06-18
Published Online: 2018-07-17
Published in Print: 2018-08-28

©2018 Malose J. Mphahlele, published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Articles in the same Issue

  1. Cover and Frontmatter
  2. Crystal structure of 2-amino-4-(2,4-dinitrophenyl)-3-cyano-7,7-dimethyl-5-oxo-4H-5,6,7,8-tetrahydrobenzo-pyran, C18H16N4O6
  3. Crystal structure of catena-poly[(μ3-5-carboxy-2-(pyridin-4-yl)benzoato-κ5O,O′:O′′,O′′′:O′′′)(1,10-phenanthroline-κ2N,N′)cadmium(II)], C100H60N12O16Cd4
  4. Crystal structure of 2-amino-4-(3,4,5-trimethoxy-phenyl)-7-methyl-5-oxo-4H,5H-pyrano[4,3-b]pyran-3-carbonitrile, C19H18N2O6
  5. Crystal structure of 1-{4-[(2-hydroxy-5-methyl benzylidene)amino]phenyl}ethanone O-ethyl-oxime, C18H20N2O2
  6. Crystal structure of bis{4-methyl-2-((E)-((4-((E)-1-(ethoxyimino)ethyl)phenyl)imino)methyl)phenolato-κ2N,O)}copper(II), C36H38CuN4O4
  7. Crystal structure of bis{5-methoxy-2-((E)-((4-((E)-1-(methoxyimino)ethyl)phenyl)imino)methyl)phenolato-κ2N,O}nickel(II), C34H34N4NiO6
  8. Crystal structure of poly[μ8-3-carboxyphthalat-κ8-O:O1,O1,O1:O2:O3,O3:O4)silver(I)], C9H4Ag2O6
  9. Crystal structure of 2-((E)-((4-((E)-1-(hydroxyimino)ethyl)phenyl)iminio)methyl)-5-methoxyphenolate, C16H16N2O3
  10. Crystal structure of (E)-1-(4-(((E)-2-hydroxy-3-methoxybenzylidene)amino)phenyl)ethan-1-one oxime, C16H16N2O3
  11. The crystal structure of 2-(tert-butyl)-4-chloro-6-phenyl-1,3,5-triazine, C13H14Cl1N3
  12. Crystal structure of (6,6′-(((((2-aminoethyl)azanediyl)bis(ethane-2,1-diyl))bis(azanylylidene))bis(methanylylidene))bis(2,4-dichlorophenolato)-κ6N,N′,N′′,N′′′,O,O′)cadmium(II) – ethanol – water (1/1/1), C22H28CdCl4N4O4
  13. Crystal structure of 6-chloro-N-methylpyrimidin-4-amine, C5H6ClN3
  14. Synthesis and crystal structure of bis{((E)-((4-((E)-1-(methoxyimino)ethyl)phenyl)imino)methyl)-2-naphtholato-κ2N,O}nickel(II), C40H34N4NiO4
  15. Crystal structure of (E)-2-(4-bromophenyl)ethenesulfonyl fluoride (C8H6BrFO2S)
  16. Synthesis and crystal structure of 2,2′-ethylenedioxybis(benzimide)-2,2′-bis[O-(1-propyloxyamide)]oxime-4,4′,6,6′-tetrachlorodiphenol, C36H34Cl4N4O8
  17. Crystal structure of bis(N-(1-(pyrazin-2-yl)ethylidene)nicotinohydrazonato-κ3N,N′,O)cadmium(II) – methanol (1/1), C26H28N10O4Zn
  18. Crystal structure of diaqua-(N-(1-(pyrazin-2-yl)ethylidene)nicotinohydrazonato-κ3N,N′,O)-bis(nitrato-κ2O,O′)samarium(III), C12H14N7O9Sm
  19. Crystal structure of hexaaqua-{(E)-N′-(1-(pyrazin-2-yl)ethylidene)isonicotinohydrazide-κ3N,N′,O}praseodym(III) trichloride monohydrate, C12H25Cl3N5O8Pr
  20. Crystal structure of methyl 4-(3-cyanophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylate, C21H22N2O3
  21. Crystal structure of ethyl 2-amino-4-(2-methoxyphenyl)-5-oxo-4H,5H-pyrano[3,2-c]chromene-3-carboxylate, C22H19NO6
  22. Crystal structure of 2,12-dibromo-5,15-dihexyl-5,15-dihydrobenzo [1,2-b:5,6-c′]dicarbazole, C38H38Br2N2
  23. Crystal structure of ethyl 2-amino-4-(3-hydroxy-4-methoxyphenyl)-5-oxo-4H,5H-pyrano[3,2-c]chromene-3-carboxylate, C22H19NO7
  24. Crystal structure of ethyl 2-amino-4-(3,4-dimethylphenyl)-5-oxo-4H,5H-pyrano[3,2-c] chromene-3-carboxylate, C23H21NO5
  25. Crystal structure of 2-hydroxy-N′-(pyrimidin-2-yl)benzohydrazide, C11H10N4O2
  26. Crystal structure of 2-(3,4-dimethylphenyl)-1,8-naphthyridine, C16H14N2
  27. Crystal structure of ethyl 4-(3,4-dimethylphenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, C23H29NO3
  28. Crystal structure of ethyl 4-(3-cyanophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, C22H24N2O3
  29. Crystal structure of 7β,9β-dihydroxy-15-oxo-ent-kauran-16-en-19,6β-olide, C20H26O5
  30. Crystal structure of Ent-7β,20-epoxy-kaur-16-en-1β,6α,7α,14α,15α-pentaol-20-one, C20H30O8
  31. Crystal structure of 1,4-bis(benzo[d][1,3]dioxol-5-ylmethyl)dihydro-1H,3H-furo[3,4-c]furan-3a(4H)-yl acetate, C22H20O8
  32. Crystal structure of methyl 2-((4-((2-nitrophenoxy)methyl)-1H-1,2,3-triazol-1-yl)methyl) benzoate, C18H16N4O5
  33. Crystal structure of diaqua-bis(5-carboxy-1-methyl-1H-imidazole-4-carboxylato-κ2N,O)zinc(II), C12H14N4O10Zn
  34. Hydrothemal synthesis and crystal structure of triaqua-bis(5-carboxy-1-methyl-1H-imidazole-4-carboxylato-κ2N,O1O)manganese(II), C12H16N4O11Mn
  35. Redetermination of methyl 4-(4-chlorophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylate, C20H22ClNO3
  36. Crystal structure of bis{1-[(benzotriazol-1-yl)methyl]-1-H-1,3-(2-methyl-imdazol)-κN}-dithiocyano-κN-zinc(II) C24H22N12S2Zn
  37. Crystal structure of (5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl furan-2-carboxylate, C10H7FN2O5
  38. Crystal structure of bis(η6-cymene)-tri-μ2-chlorido-ruthenium(II) tetrafluoroborate, C20H28BCl3F4Ru2
  39. Crystal structure of 3,6-diphenyl-7H-[1,2,4]-triazolo[3,4-b][1,3,4]thiadiazine, C16H12N4S
  40. Synthesis and crystal structure of 1,3-bis[(3,4-dicyano)phenoxy]-4,6-dinitro-benzene, C22H8N6O6
  41. Crystal structure of ethyl 2-amino-4-(2,6-dichlorophenyl)-7-methyl-5-oxo-4H,5H-pyrano [4,3-b]pyran-3-carboxylate, C18H15Cl2NO5
  42. Crystal structure of poly[μ3-hydroxy-(μ5-(5-(2-carboxylatophenoxy)isophthalato-κ6O1:O2:O3:O4:O5,O6)-(μ2-1,4-di(1H-imidazol-1-yl)butane-κ2N:N′)dicobalt(II)] hemihydrate, C25H22Co2N4O8.5
  43. Crystal structure of methyl 4-(4-bromophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, C20H22BrNO3
  44. Crystal structure of 9,10-dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium 5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-olate trihydrate, C35H33NO12
  45. Crystal structure of 2,5-bis(4-(10H-phenothiazin-10-yl)phenyl)-1,3,4-oxadiazole, C38H24N4OS2
  46. The crystal structure of (E)-2-(4-hydroxyphenyl)-5-(prop-1-en-1-yl)benzofuran-3-carbaldehyde, C18H14O3
  47. Crystal structure of bis{5H-dibenzo[c,f][1,5]oxabismocin-12(7H)-yl} carbonate, C29H24O5Bi2
  48. Crystal structure of ethyl-5-formyl-3,4-dimethylpyrrole-2-carboxylate — N-(5-ethoxycarbonyl-3,4-dimethylpyrrole)-2-methylene-5-nitrobenzene-1,2-diamine (1:1), C26H31N5O7
  49. Crystal structure of (E)-2-(1-((2-aminophenyl)imino)ethyl)-6-bromo-4-chlorophenol, C14H12BrClN2O
  50. Crystal structure of (Z)-2-(4-chlorophenyl)-4-(furan-2-yl(phenylamino)methylene)-5-methyl-2,4-dihydro-3H-pyrazol-3-one, C21H16ClN3O2
  51. Crystal structure of N2,N4-dibutyl-6-chloro-N2,N4-bis(1,2,2,6,6-pentamethylpiperidin-4-yl)-1,3,5-triazine-2,4-diamine, C31H58ClN7 – Important intermediate of Chimassorb 119 synthesis
  52. Crystal structure of 1-(5-bromo-2-(4-methoxyphenyl)-1H-indol-7-yl)ethanone oxime, C17H15BrN2O2
  53. Crystal structure of poly-{diaqua-bis[(μ2-3-nitrobenzenesulfonylglycine-κ3N:O:O′)(4,4′-bipyridine)manganese(II)]}-dimethylformamide (1/1), C39H35Mn2N9O15S2
  54. Crystal structure of 4-(dimethylamino)-1-(prop-2-yn-1-yl)pyridin-1-ium perchlorate, C10H13ClN2O4
  55. Crystal structure of 2-amino-5-oxo-4-(4-chloro-phenyl)-4,5,6,7-tetrahydro-cyclopenta[b]pyran-3-carbonitrile, C15H11ClN2O2
  56. Crystal structure of triaqua-(pyridine-2,6-dicarboxylato-κ3O,N,O′)cobalt(II) – 6-phenyl-1,3,5-triazine-2,4-diamine (1/1), C16H18CoN6O7
  57. Crystal structure of ethyl 2-amino-4-(3-cyanophenyl)-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carboxylate, C21H22N2O4
  58. Crystal structure of 2-(4-chloro-2,6-dinitrophenyl)-1-(4-chloro-3-nitrophenyl)diazene 1-oxide, C12H5Cl2N5O7
  59. Crystal structure of 3,4-dimethyl-2,6-dinitrophenol, C8H8N2O5
  60. Crystal structure of 1,2-dimethyl-3,5-dinitrobenzene, C8H8N2O4
  61. Crystal structure of ethyl 4-(3-chlorophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, C21H24ClNO3
  62. Crystal structure of N-(4-chlorophenyl)-2-(2,6-dichlorophenyl)acetamide, C14H10Cl3NO
  63. Crystal structure of 2-amino-4-(4-fluorophenyl)-3-cyano-5-oxo-4H,5H-pyrano[3,2c] chromene, C19H11FN2O3
  64. The crystal structure of (4-nitrophenyl) (5-ferrocenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl) methanone, C21H12F3FeN3O3
  65. Crystal structure of 5,5′-((3-hydroxy-4-methoxyphenyl)methylene)bis(1,3-diethyl-6-hydroxy-2-thioxo-2,3-dihydropyrimidin-4(1H)-one), C24H30N4O6S2
  66. Crystal structure of (3aR,4R,5R,7R,8S,9R,9aS,12R)-7-ethyl-5-(1-hydroxy-2-((R)-3-hydroxypyrrolidin-1-yl)ethoxy)-4,7,9,12-tetramethyldecahydro-4,9a-propanocyclopenta[8]annulene-3,8-diol – a pleuromutilin derivative, C26H41NO5
  67. Crystal structure of bis(μ2-3-formyl-5-methoxy-2-oxidobenzoato-κ3O,O′:O′)-hexapyridine-dicadmium(II) – pyridine (1/1), C53H47Cd2N7O10
  68. Crystal structure of ethyl 2-amino-4-(3-methoxyphenyl)-5-oxo-4H,5H-pyrano[3,2-c]chromene-3-carboxylate, C22H19NO6
  69. Crystal structure of methyl 4-(3,5-ditrifluoromethylphenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate — water (2/1), C22H21F6NO3
  70. Crystal structure of 2-(4-bromophenyl)-2,3-dihydro-1H-perimidine, C17H13BrN2
  71. Crystal structure of (5-ethyl-2-(4-methoxyphenyl)-1,3-dioxan-5-yl)methanol, C14H20O4
  72. Crystal structure of (E)-N-(4-bromo-2-(1-(hydroxyimino)ethyl)phenyl)benzamide, C15H13BrN2O2
  73. Crystal structure of caffeinium triiodide – caffeine (1/1), C16H21I3N8O4
  74. Crystal structure of methyl 2-methyl-4-(3-methoxyphenyl)-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, C19H21NO4
  75. Crystal structure of (E)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-1-phenylprop-2-en-1-one, C23H28O2
  76. Crystal structure of 1,4-bis(2-azidoethyl)piperazine-1,4-diium dichloride, C8H18N8Cl2
  77. The crystal structure of dichlorido-(1,3-bis(2,6-dimethylphenyl)-1H-imidazol-2(3H)-ylidene)-(morpholine-κ1N)palladium(II), C23H29Cl2N3OPd(II)
  78. The crystal structure of 1-((5-chloro-3-methyl-1-phenyl-1H-pyrazole-4-yl)methyl)-1,3-diphenylurea, C24H21ClN4O
  79. Crystal structure of 6-(2-bromoacetamido)tetrahydro-2H-pyran-2,3,4,5-Tetrayl tetraacetate, C16H22BrNO10
  80. Crystal structure of 5-methylpyrazine-2-carbohydrazide, C6H8N4O
  81. Crystal structure of catena-poly[(μ2-5-(tert-butyl)isophthalato-κ4O,O′:O′′,O′′′)(-4′-(pyridin-4-yl)-2,2′:6′,2′′-terpyridine-κ3N,N′,N′′)manganese(II)], C32H28N4O5Mn
Downloaded on 19.12.2025 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2018-0081/html?srsltid=AfmBOorNfXy4Q6UUVh8cYmHXEJ4yq2IhBpZJjDCJz3AGxyZNdXjG3RYO
Scroll to top button